| Company Name: |
Guangzhou PI PI Biotech Inc
|
| Tel: |
+86-020-81716320 +86-13602409664 |
| Email: |
Sales@pipitech.com |
| Products Intro: |
Product Name:Aprepitant-d4
CAS:1133387-60-6
Purity:90%+ Package:10mg, 25mg, 50mg, 100mg, Other scale please email Sales@pipitech.com Remarks:5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl-d4)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Tel: |
010-82848833 400-666-7788 |
| Email: |
jkinfo@jkchemical.com |
| Products Intro: |
Product Name:Aprepitant-d4
CAS:1133387-60-6
Package:10Mg,1Mg
|
| Company Name: |
Cato Research Chemicals Inc.
|
| Tel: |
020-81960175 |
| Email: |
min.he@cato-chem.com |
| Products Intro: |
Product Name:Aprepitant-d4
CAS:1133387-60-6
Purity:95% Package:25Mg, 50Mg
|
|
| | Aprepitant-d4 Basic information |
| Product Name: | Aprepitant-d4 | | Synonyms: | Aprepitant-d4;5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(2,3,5,6-tetradeuterio-4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one;5-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl-2,3,5,6-d4)morpholino)methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;[2H4]-Aprepitant;Aprepitant D4Q: What is
Aprepitant D4 Q: What is the CAS Number of
Aprepitant D4 Q: What is the storage condition of
Aprepitant D4 Q: What are the applications of
Aprepitant D4 | | CAS: | 1133387-60-6 | | MF: | C23H17D4F7N4O3 | | MW: | 538.451309512 | | EINECS: | | | Product Categories: | Chiral Reagents, Heterocycles, Isotope Labelled Compounds, Pharmaceuticals, Intermediates & Fine Chemicals | | Mol File: | 1133387-60-6.mol |  |
| | Aprepitant-d4 Chemical Properties |
| Melting point | 242-244°C | | storage temp. | -20°C Freezer | | solubility | DMSO (Slightly), Methanol (Slightly, Sonicated) | | form | Solid | | color | White to Off-White |
| | Aprepitant-d4 Usage And Synthesis |
| Uses | Aprepitant-d4 is a labeled analogue of Aprepitant (A729800), A novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. Aprepitant-d4 is a potential treatment for chemotherapy induced nausea and vomiting. |
| | Aprepitant-d4 Preparation Products And Raw materials |
|